

Received: 2019.03.18
Accepted: 2019.03.18
Published: 2019.03.29

Re: Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence From an International Randomized Trial of Everolimus-Based Immunosuppression

BDF 1 **Faouzi Saliba**
BDF 2 **Lutz Fischer**
BDF 3 **Paolo de Simone**
CDF 4 **Peter Bernhardt**
CDF 4 **Giovanni Bader**
BDF 5 **John Fung**

1 Hepato-Biliary Center, AP-HP Hôpital Paul Brousse, Université Paris-Sud, Villejuif, France
2 Department of Hepatobiliary Surgery and Transplantation, University Medical Center Eppendorf, Hamburg, Germany
3 Hepatobiliary Surgery and Liver Transplantation, University of Pisa, Pisa, Italy
4 Novartis Pharma AG, Basel, Switzerland
5 Transplantation Center, Cleveland Clinic, Cleveland, OH, U.S.A.

Corresponding Author: Faouzi Saliba, e-mail: faouzi.saliba@pbr.aphp.fr

Ann Transplant. 2018 Oct 26;23:751-757. doi: 10.12659/AOT.911030.
PMID: 30361470, PMCID: PMC6248043

In the paper, the sentence on page 754, first column, lines 4, 5, and 6 has been incorrectly written:
At the month 24 study visit, mean (SD) eGFR was 74.7 (26.1), 67.8 (21.0), and 77.5 (26.2) mL/min/1.73 m² in the EVR/rTAC, **TAC Elimination, and TAC Control groups**, respectively (p=0.007).
The corrected sentence should read:
At the 24-month study visit, mean (SD) eGFR was 74.7 (26.1), 67.8 (21.0), and 77.5 (26.2) mL/min/1.73 m² in the EVR/rTAC, **TAC Control, and TAC Elimination groups**, respectively (p=0.007).

Full-text PDF: <https://www.annalsoftransplantation.com/abstract/index/idArt/916307>

